Kirk Randal J

recently revealed that they own a 43.7% stake in Fibrocell Science Inc (NASDAQ:FCSC) in a Form 13D/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Wednesday, December 13th. The investor owns 10,994,686 shares of the stock worth $6,926,652. The reporting parties listed on the disclosure included Randal J Kirk, Irs Identification No: 541923091, Irs Identification No: 271471440 and Irs Identification No: 260084895. The disclosure is available through the SEC website at this link.

Kirk Randal J

provided the following explanation of their ownership:

Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows:
The information set forth in Items 3 and 6 is incorporated herein by reference.
NRM VII Holdings, Kapital Joe and Mascara Kaboom acquired the shares disclosed hereunder for investment purposes.
CUSIP No. 315721100
Page 7 of 9

Separately, Pura Vida Investments LLC acquired a new stake in shares of Fibrocell Science in the 3rd quarter valued at approximately $909,000. Institutional investors and hedge funds own 55.81% of the company’s stock.

Fibrocell Science Inc (NASDAQ FCSC) traded down $0.04 on Wednesday, reaching $0.63. The company had a trading volume of 478,700 shares, compared to its average volume of 116,327. Fibrocell Science Inc has a twelve month low of $0.61 and a twelve month high of $4.64.

Several equities research analysts have recently commented on the company. Canaccord Genuity reissued a “buy” rating and issued a $7.00 price objective (up previously from $3.00) on shares of Fibrocell Science in a report on Monday, September 11th. HC Wainwright restated a “buy” rating and issued a $5.70 price target on shares of Fibrocell Science in a research note on Friday, September 15th. Zacks Investment Research upgraded Fibrocell Science from a “sell” rating to a “hold” rating in a research note on Friday, September 15th. Finally, ValuEngine cut Fibrocell Science from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $5.21.

WARNING: This piece was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Institutional Ownership by Quarter for Fibrocell Science (NASDAQ:FCSC)

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with's FREE daily email newsletter.